Safe Sips Act of 2026
- Sponsor
- Rep. LaLota, Nick [R-NY-1]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jul 23, 2026
Bottom line
The Safe Sips Act of 2026 mandates a uniform color-coding and non-color identification system for the packaging of various intoxicating beverages to enhance consumer awareness and prevent accidental consumption of intoxicating substances.
What it actually does
This bill directs the Secretary of Health and Human Services (acting through the FDA) and the Secretary of the Treasury (acting through the TTB) to establish a uniform color-coding system for the packaging of 'covered drinks' at their dispensing point. Covered drinks include alcohol, THC, intoxicating cannabinoids, Kratom-related substances, and other intoxicating substances determined by the Secretary. The system must also include a non-color identifier for accessibility, and the bill prohibits the use of the designated color on non-covered drinks. It mandates compliance for manufacturers, distributors, and retailers, and establishes civil penalties for non-compliance, while preempting any additional or more stringent state, local, or Tribal regulations.
Proponents argue
Proponents would argue that this bill is a crucial public safety measure designed to protect consumers, especially children and those with visual impairments, from accidentally consuming intoxicating substances. They would emphasize the growing market for various psychoactive drinks and the need for clear, universal labeling to prevent confusion and reduce harm. The preemption clause ensures a consistent national standard, simplifying compliance for manufacturers and retailers while maximizing public health benefits.
Opponents contend
Opponents might argue that the bill imposes an unnecessary and burdensome regulatory framework on manufacturers, distributors, and retailers, potentially leading to significant compliance costs that could be passed on to consumers. They might also contend that existing labeling requirements are sufficient, or that a single color-coding system could be oversimplified and fail to convey the nuanced risks associated with different intoxicating substances. Furthermore, the preemption clause could be seen as infringing on states' rights to implement more stringent or tailored public health regulations.
The bill is short and relatively straightforward, allowing a reader to grasp its core intent and mechanisms quickly.
Section 2(a)
Establishment of a Uniform Color-Coding System
This provision directs the Secretary (HHS/FDA and Treasury/TTB) to create a system for color-coding the packaging of 'covered drinks' at their dispensing point. It mandates a single color for all intoxicating substances covered by the Act and requires a non-color identifier (text, symbol, tactile feature) to ensure accessibility for blind or colorblind consumers. It also requires technical specifications for 'substantially similar color' for enforcement.
Supporters argue
Supporters argue this system provides a clear, immediate visual cue for consumers, reducing the risk of accidental ingestion, especially for vulnerable populations like children. The non-color identifier ensures inclusivity.
Critics contend
Critics may argue that a single color might not adequately differentiate between various types and potencies of intoxicating substances, potentially leading to a false sense of security or confusion. They might also point to the cost of redesigning packaging.
Tradeoffs
Balances the need for universal clarity and accessibility against the potential for oversimplification and the costs associated with industry-wide packaging changes.
Section 2(b)
Industry Compliance and Information Dissemination
This section outlines the responsibilities for implementing the color-coding system. Manufacturers must implement the system, distributors and retailers must disseminate information about it to consumers, and retailers must ensure all covered drinks sold comply. Crucially, it prohibits any manufacturer, distributor, or retailer from using the designated color (or a substantially similar color) on non-covered drinks.
Section 2(c)
Civil Penalties for Non-Compliance
This provision directs the Secretary to establish a procedure for assessing civil penalties against manufacturers, distributors, or retailers who fail to comply with the requirements of subsection (b). It also mandates the creation of a structure for determining the amount of such fines.
Section 2(e)
Federal Preemption of State and Local Regulations
This section explicitly states that no State, political division of a State, or Tribal government may enact, adopt, promulgate, or enforce any law, regulation, or other requirement that is in addition to, or more stringent than, a requirement or prohibition established under this Act.
Section 2(g)(3)
Broad Definition of "Covered Substance"
This provision defines "covered substance" to include alcohol, THC (including delta-8, delta-9, delta-10, regardless of source or derivation), intoxicating cannabinoids (isomers, derivatives, analogues, homologs, synthetic, with intoxicating effect similar to or greater than THC), Kratom-related substances (Mitragyna speciosa Korth., Mitragynine, 7-hydroxymitragynine), and any other intoxicating substance determined by the Secretary.
The Act applies to covered drinks manufactured, distributed, sold, or offered for sale on or after the date that is 4 years after the date of enactment.
Section 2(h)
Why it matters:Standard legislative practice to place applicability dates at the end of a section.
Case for: Provides a substantial transition period (4 years) for manufacturers, distributors, and retailers to comply with the new packaging and information dissemination requirements, minimizing immediate disruption and allowing for necessary retooling and inventory adjustments.
Case against: Critics might argue that a 4-year delay in implementation postpones crucial public safety benefits, especially given the rapid evolution of the market for various intoxicating substances. They might contend that the urgency of the issue warrants a faster rollout.
Estimated impact: Delays the public health benefits and industry compliance costs for four years post-enactment.